Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events. Here the authors describe factor Xa variants that are refractory to inhibition by these anticoagulants and c...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniël Verhoef, Koen M. Visscher, C. Ruben Vosmeer, Ka Lei Cheung, Pieter H. Reitsma, Daan P. Geerke, Mettine H. A. Bos
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Q
Online Access:https://doaj.org/article/b141be2853c5434db46bb976a6a0ac12
Tags: Add Tag
No Tags, Be the first to tag this record!